Usami M
Department of Urology Osaka Medical Center for Cancer and Cardiovascular Disease, Japan.
Gan To Kagaku Ryoho. 1998 May;25(6):817-22.
Endocrine therapy for prostate cancer has been changing rapidly. While LH-RH agonists have been popularly used in medication, their long-acting sustained release formulation is about to be introduced to clinics in Japan. LH-RH antagonists, which have not attracted much attention of clinicians because of adverse reactions, are also going to be put into practical use in the near future. Bicalutamide, which is considered to have greater usefulness than other anti-androgens, is now under regulatory review by the authorities for approval. In addition, a broader range of endocrine therapies is being studied for treatment of prostate cancer. In terms of treatment methods, a number of attempts are made in selection of subject patients, treatment timing, combination treatment and so on.
前列腺癌的内分泌治疗一直在迅速变化。虽然促黄体生成素释放激素（LH-RH）激动剂在药物治疗中已被广泛使用，但其长效缓释制剂即将在日本引入临床。促黄体生成素释放激素拮抗剂由于不良反应尚未引起临床医生太多关注，但也将在不久的将来投入实际应用。比卡鲁胺被认为比其他抗雄激素药物更具疗效，目前正在接受当局的监管审查以获得批准。此外，正在研究更广泛的内分泌治疗方法用于前列腺癌的治疗。在治疗方法方面，在选择受试患者、治疗时机、联合治疗等方面进行了许多尝试。
